Wells Fargo & Company Cytom X Therapeutics, Inc. Transaction History

Wells Fargo & Company

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.41 - $2.74 $12 - $24	9 Added 1.75%	524 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $1.55 $29 - $43	28 Added 5.75%	515 $0
Q3 2023 Nov 13, 2023	BUY	$1.26 - $1.87 $11 - $16	9 Added 1.88%	487 $0
Q2 2023 Aug 15, 2023	BUY	$1.41 - $1.92 $29 - $40	21 Added 4.6%	478 $0
Q1 2023 May 12, 2023	BUY	$1.48 - $2.88 $10 - $20	7 Added 1.56%	457 $0
Q4 2022 Feb 13, 2023	BUY	$1.19 - $1.91 $14 - $22	12 Added 2.74%	450 $0
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $38 - $61	31 Added 7.62%	438 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.53 - $2.89 $129,780 - $245,141	-84,824 Reduced 99.52%	407 $1,000
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $51,779 - $90,759	-19,393 Reduced 18.54%	85,231 $228,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $54,392 - $103,866	14,055 Added 15.52%	104,624 $452,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $162,393 - $241,710	37,591 Added 70.96%	90,569 $460,000
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $580,948 - $909,510	-91,777 Reduced 63.4%	52,978 $335,000
Q1 2021 May 13, 2021	BUY	$6.6 - $9.0 $296,604 - $404,460	44,940 Added 45.02%	144,755 $1.12 Million
Q4 2020 Feb 09, 2021	SELL	$6.47 - $7.9 $48,499 - $59,218	-7,496 Reduced 6.99%	99,815 $654,000
Q3 2020 Nov 05, 2020	BUY	$6.55 - $8.83 $43,898 - $59,178	6,702 Added 6.66%	107,311 $714,000
Q2 2020 Aug 13, 2020	BUY	$7.4 - $14.64 $545,572 - $1.08 Million	73,726 Added 274.25%	100,609 $838,000
Q1 2020 May 14, 2020	BUY	$3.61 - $8.6 $97,047 - $231,193	26,883 New	26,883 $206,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.